At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 768 enrolled
Drug / intervention
TRV130drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute Pain for Which Parenteral Opioid Therapy is Warranted
In Brief
A Phase 3 clinical trial evaluating TRV130 for Acute Pain. Completed, enrolled 768 participants across 10 sites.
Detailed Summary
Patients with moderate to severe pain caused by medical conditions or surgery, who require IV opioid therapy may be enrolled in this open label safety study. Patients will be treated with TRV130 by IV bolus, PCA (patient-controlled analgesia) administration, or both, as determined by the investigator, for a duration not to exceed 14 days.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Pain
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartDec 2015
First PostedJan 2016
Primary CompletionMay 2017
Study CompletionAug 2017
TodayJul 2026
First PostedJan 15, 2016
Enrollment StartDec 1, 2015
Primary CompletionMay 1, 2017
Study CompletionAug 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 10.5 years ago
Interventions
TRV130drug